Aptorum Group Limited - Class A Ordinary Shares (APM): Price and Financial Metrics
GET POWR RATINGS... FREE!
APM Stock Summary
- APM has a market capitalization of $19,065,539 -- more than approximately only 6.62% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.03 for APTORUM GROUP LTD; that's greater than it is for merely 5.87% of US stocks.
- Revenue growth over the past 12 months for APTORUM GROUP LTD comes in at 129.9%, a number that bests 93.67% of the US stocks we're tracking.
- Stocks that are quantitatively similar to APM, based on their financial statements, market capitalization, and price volatility, are TDUP, HCWB, TVTX, FBIO, and ZLAB.
- APM's SEC filings can be seen here. And to visit APTORUM GROUP LTD's official web site, go to www.aptorumgroup.com.
APM Valuation Summary
- In comparison to the median Healthcare stock, APM's EV/EBIT ratio is 116.28% lower, now standing at -1.4.
- Over the past 48 months, APM's price/earnings ratio has gone up 59.9.
Below are key valuation metrics over time for APM.
APM's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- APM has a Quality Grade of C, ranking ahead of 44.63% of graded US stocks.
- APM's asset turnover comes in at 0.027 -- ranking 360th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows APM's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
APM Stock Price Chart Interactive Chart >
APM Price/Volume Stats
|Current price||$0.56||52-week high||$2.35|
|Prev. close||$0.53||52-week low||$0.48|
|Day high||$0.56||Avg. volume||793,892|
|50-day MA||$0.80||Dividend yield||N/A|
|200-day MA||$1.23||Market Cap||19.78M|
Aptorum Group Limited - Class A Ordinary Shares (APM) Company Bio
Aptorum Group Ltd. is a pharmaceutical company, which engages in the development and commercialization of therapeutic and diagnostic technologies. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The Non-Therapeutics segment encompasses the development of surgical robotics and medical devices; and the activities of AML Clinic. The company was founded by Ian Huen on September 13, 2010 and is headquartered in Hong Kong.
Most Popular Stories View All
APM Latest News Stream
|Loading, please wait...|
APM Latest Social Stream
View Full APM Social Stream
Latest APM News From Around the Web
Below are the latest news stories about APTORUM GROUP LTD that investors may wish to consider to help them evaluate APM as an investment opportunity.
RedChip Companies will air a new interview Aptorum Group Limited (NASDAQ:APM)(Euronext Paris:APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, on The RedChip Money Report® on Bloomberg TV, this Saturday, November 26, at 7 p.m. Eastern Time (ET).
Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)
NEW YORK & LONDON & PARIS, November 25, 2022--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune diseases and infectious diseases, is pleased to announce the recent publication of a joint effort for the validated analytical method developed for the determination of plasma pro-EGCG and its metabolites after oral administration using ultra performance liquid chromatog
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock
NEW YORK & LONDON & PARIS, November 08, 2022--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold its 2022 annual general meeting of shareholders at its London office located at 4T.07, 17 Hanover Square, Mayfair London, England W1S 1BN at 12:00 noon London Time on Decem
HC Wainwright initiated coverage on Aptorum Group Limited (NASDAQ: APM) with a Buy rating and a price target of $8. The analyst is bullish on Aptorum based on three points: Promising preclinical efficacy of lead product candidate ALS-4, both on a standalone basis and in combination with standard of care vancomycin, against Staphylococcus aureus (SA) infection. Blockbuster potential of SACT-1’s in vivo neuroblastoma tumor reduction effects in combination with SOC chemotherapy The significant pote
APM Price Returns